close

Join our Mailing List

Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.

Search Results for: compass – Page 2

Dr. Saumik Biswas and founders of Tenomix Inc.
FACIT pitch competition empowers Ontario’s oncology entrepreneurs
Falcons’ Fortunes gives Ontario innovators the chance to showcase their innovations each year for a chance at the $100,000 Ernsting Entrepreneurship Award, with much of FACIT’s support happening behind the scenes. For Dr. Saumik Biswas and the entrepreneurs behind the robotic ultrasound technology...
Genome sequencing in lab
Genome sequencing delivers real-time results for hard-to-treat pancreatic cancer
OICR’s PanCuRx program is unlocking the mysteries behind Canada’s fourth leading cause of cancer death and translating knowledge into better treatment options. Tough to detect, quick to spread and stubbornly resistant to treatment, pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms...
The Prospects Fund logo
Two OICR innovations bolstered by investments from FACIT
Investments will support high-profile work led by Dr. Rima Al-awar and Dr. Lincoln Stein. Groundbreaking projects in OICR’s Drug Discovery and Adaptive Oncology research themes are receiving support to advance made-in-Ontario innovations thanks to investments from FACIT. The investments announced...
steve-rectangle
OICR appoints Dr. Steven Gallinger as Head, Clinical Translation
Gallinger brings more than three decades of clinical and interdisciplinary research experience to OICR leadership Dr. Steven Gallinger has joined OICR’s executive leadership team as Head, Clinical Translation. In this role, he will lead one of OICR’s three key priority areas, Clinical Translation,...
PDAC
Clinical study simplifies precision medicine for pancreatic cancer patients
Liver biopsy image from a patient with metastatic pancreatic ductal adenocarcinoma. Dual immunohistochemistry reveals expression of GATA6 (brown) or CK5 (magenta) in distinct cells within the same neoplastic glands. (Credit: Clinical Cancer Research) OICR-supported researchers discover new way to match...
NeoPancONE
OICR research leads to new pancreatic cancer clinical trial with aim to change the standard of care for patients
New pancreatic cancer trial, NeoPancONE, launches across Canada Adapted from Pancreatic Cancer Canada’s press release. OICR’s PanCuRx team and collaborators have launched NeoPancONE, a Phase II clinical trial that will evaluate a potentially curative treatment strategy for operable pancreatic...
oicr-cfhu-logo-block
Philanthropic donation moves The Alex U. Soyka Pancreatic Cancer Research Project: An International Partnership into Phase II
Ontario-Israel collaboration to explore personalized treatment and improved diagnostics for pancreatic cancer Toronto – (June 24, 2020) A second significant multi-year commitment from Sylvia M. G. Soyka, Director, and the Alex U. Soyka Foundation to the Canadian Friends of the Hebrew University of...
Notta_Gallinger
Unique Toronto-based clinical trial reveals new subtypes of advanced pancreatic cancer
Researchers identify five subtypes of pancreatic cancer, uncovering new opportunities for targeted treatment of the aggressive disease Toronto – (January 13, 2020) Researchers at the Ontario Institute for Cancer Research (OICR) and the University Health Network (UHN) have discovered detailed new information...
facit-headshots
FACIT launches assessment of venture philanthropy models to scale Canadian commercialization of cancer research
TORONTO, ON (November 6, 2019) – FACIT, a commercialization venture venture firm, reported on the expansion of its Executive-in-Residence program and new strategic initiatives. Ontario is home to world-leading cancer research connected through the collaboration model established by the Ontario Institute...
cellular-logo
FACIT and University of Toronto launch precision medicine company: Cellular Analytics
Next generation liquid biopsy platform to revolutionize companion diagnostics TORONTO, ON (October 30, 2019) – FACIT, a commercialization venture group, together with the University of Toronto (“U of T”), announced the creation of Ontario-based Cellular Analytics (the “Company”). Cellular Analytics...
Dr. Saumik Biswas and founders of Tenomix Inc.

FACIT pitch competition empowers Ontario’s oncology entrepreneurs

Falcons’ Fortunes gives Ontario innovators the chance to showcase their innovations each year for a chance at the $100,000 Ernsting Entrepreneurship Award, with much of FACIT’s support happening behind the scenes. For Dr. Saumik Biswas and the entrepreneurs behind the robotic ultrasound technology code-named the ‘Lymphonator’, the 2021 FACIT Falcons’ Fortunes competition was a valuable learning experience. Biswas and his team from Western University are experts in their field, creators

Genome sequencing in lab

Genome sequencing delivers real-time results for hard-to-treat pancreatic cancer

OICR’s PanCuRx program is unlocking the mysteries behind Canada’s fourth leading cause of cancer death and translating knowledge into better treatment options. Tough to detect, quick to spread and stubbornly resistant to treatment, pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Most people won’t have symptoms in the early stages, giving pancreatic tumours — which can metastasize when they’re no bigger than a fingernail — plenty

The Prospects Fund logo

Two OICR innovations bolstered by investments from FACIT

Investments will support high-profile work led by Dr. Rima Al-awar and Dr. Lincoln Stein. Groundbreaking projects in OICR’s Drug Discovery and Adaptive Oncology research themes are receiving support to advance made-in-Ontario innovations thanks to investments from FACIT. The investments announced on April 27 will support work led by OICR’s Head of Therapeutic Innovation and Drug Discovery Dr. Rima Al-awar and Head of Adaptive Oncology Dr. Lincoln Stein. Dr. Al-awar’s Drug

OICR appoints Dr. Steven Gallinger as Head, Clinical Translation

Gallinger brings more than three decades of clinical and interdisciplinary research experience to OICR leadership Dr. Steven Gallinger has joined OICR’s executive leadership team as Head, Clinical Translation. In this role, he will lead one of OICR’s three key priority areas, Clinical Translation, which focuses on advancing Ontario cancer discoveries through early clinical validation, partnering with industry and the health system for downstream development and implementation. Gallinger has more than

Clinical study simplifies precision medicine for pancreatic cancer patients

OICR-supported researchers discover new way to match advanced pancreatic cancer patients with the most appropriate treatment for their disease Over the next 10 years, it is expected that pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related deaths in North America. Precision medicine for PDAC is dependent on understanding which cancers will respond to treatment and which will not, but progress in this space has been limited

OICR research leads to new pancreatic cancer clinical trial with aim to change the standard of care for patients

New pancreatic cancer trial, NeoPancONE, launches across Canada Adapted from Pancreatic Cancer Canada’s press release. OICR’s PanCuRx team and collaborators have launched NeoPancONE, a Phase II clinical trial that will evaluate a potentially curative treatment strategy for operable pancreatic cancer. The trial, which is supported by Pancreatic Cancer Canada, will recruit patients at 10 cancer centres across the country to evaluate the effectiveness and feasibility of peri-operative chemotherapy – chemo

Philanthropic donation moves The Alex U. Soyka Pancreatic Cancer Research Project: An International Partnership into Phase II

Ontario-Israel collaboration to explore personalized treatment and improved diagnostics for pancreatic cancer Toronto – (June 24, 2020) A second significant multi-year commitment from Sylvia M. G. Soyka, Director, and the Alex U. Soyka Foundation to the Canadian Friends of the Hebrew University of Jerusalem (CFHU) will allow researchers from the Ontario Institute for Cancer Research (OICR), the Hebrew University’s Institute for Medical Research Israel-Canada (IMRIC) and Sheba Medical Center to

Unique Toronto-based clinical trial reveals new subtypes of advanced pancreatic cancer

Researchers identify five subtypes of pancreatic cancer, uncovering new opportunities for targeted treatment of the aggressive disease Toronto – (January 13, 2020) Researchers at the Ontario Institute for Cancer Research (OICR) and the University Health Network (UHN) have discovered detailed new information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease. The

FACIT launches assessment of venture philanthropy models to scale Canadian commercialization of cancer research

TORONTO, ON (November 6, 2019) – FACIT, a commercialization venture venture firm, reported on the expansion of its Executive-in-Residence program and new strategic initiatives. Ontario is home to world-leading cancer research connected through the collaboration model established by the Ontario Institute for Cancer Research (OICR), FACIT’s strategic partner. Growing market signals suggest Canadian philanthropy, oncologists and patients want more discoveries translated into therapies and technologies that directly impact cancer care, while

FACIT and University of Toronto launch precision medicine company: Cellular Analytics

Next generation liquid biopsy platform to revolutionize companion diagnostics TORONTO, ON (October 30, 2019) – FACIT, a commercialization venture group, together with the University of Toronto (“U of T”), announced the creation of Ontario-based Cellular Analytics (the “Company”). Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells. The technology quantitatively detects sensitivity to immune-oncology agents ‘on-chip’